Lexeo Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 24, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 24, 2025
LXEO$3.06-2.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Financial Statements and Supplementary Data
LEXEO THERAPEUTICS, INC.
INDEX TO FINANCIAL STATEMENTS
| Report of Independent Registered Public Accounting Firm (KPMG LLP, New York, NY, Auditor Firm ID: 185) | 113 |
|---|---|
| Balance Sheets | 114 |
| Statements of Operations and Comprehensive Loss | 115 |
| Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit) | 116 |
| Statements of Cash Flows | 117 |
| Notes to Financial Statements | 118 |
KPMG LLP
345 Park Avenue
New York, NY 10154-0102
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.